Product Description
a novel ligand of the nociceptin/orphanin FQ (N/OFQ) peptide receptor, NOP. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12237257/)
Mechanisms of Action: NOP Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zealand Pharma
Company Location: COPENHAGEN G7 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Failure|Heart Failure, Acute|Heart Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-004801-11 | P2 |
Active, not recruiting |
Heart Failure, Chronic|Heart Failure, Acute |
2005-06-18 |
|
NCT00283361 | P2 |
Terminated |
Heart Failure |
None |